Conclusion
- The therapy with Rituximab shows high response rates and appears to be effective in the elimination of inhibitors.
- Whether the success of the inhibitor elimination by Rituximab correlated to the inhibitor titer is unknown.
- Further studies are needed to confirm whether Rituximab has a role in the first line therapy compared with other therapy regimens, or only in cases unresponsive to other immunomodulatory treatments.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Cohen AJ, Kessler CM. Acquired inhibitors. In: Lee CA, ed. Haemophilia. Bailliere’s Clinical Haematology 1996; 9: 331–354
Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200–203
Kain S, Copeland T-S, Leahy M F. Treatment of refractory autoimmune (acquired) haemophilia with anti-CD20 (Rituximab) Br J Haematol 2002; 119: 572–580
Karwal MW, Schlueter AJ, Zenk DW, Davis RT. Treatment of acquired factor VIII deficiency with rituximab. [abstract] Blood 2001; 98: 533a
Kessler CM, Nemes L. Acquired inhibitors to factor VIII. In: Rodriguez-Merchan EC and Lee CA Inhibitors in patients with haemophilia. Blackwell Science 2002; 98–112
Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Sem Thromb Haemostas 1975; 1: 336–385
Stasi R, Brunetti M, Stpa E, Amadori S. Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood 2004
Wiestner A, Cho HJ, Asch AS, Michelis AM, Zeller JA, Peerschke EI, Weksler BB, and Schechter GP. Rituximab in the treatment of acquired factor VIII inhibitors. Blood 2002; 100: 3426–3428
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Verlag Berlin Heidelberg
About this paper
Cite this paper
Krause, M., von Auer, C., Stier-Brück, I., Scharrer, I. (2006). Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII. In: Scharrer, I., Schramm, W. (eds) 35th Hemophilia Symposium. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-28546-6_37
Download citation
DOI: https://doi.org/10.1007/3-540-28546-6_37
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-28543-4
Online ISBN: 978-3-540-28546-5
eBook Packages: MedicineMedicine (R0)